⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884670 | 0.79 | IGF1R (0.34) | — | |
| SCHEMBL3727464 | 0.79 | IGF1R (0.41) | — | |
| SCHEMBL4888699 | 0.79 | MAPT (0.34) | — | |
| SCHEMBL4884585 | 0.79 | IGF1R (0.36) | — | |
| SCHEMBL4890256 | 0.78 | NAMPT (0.40) | — | |
| SCHEMBL4879679 | 0.78 | NR1H2 (0.36) | — | |
| SCHEMBL5480183 | 0.77 | AR (0.46) | — | |
| SCHEMBL2940400 | 0.77 | IGF1R (0.35) | — | |
| SCHEMBL3737891 | 0.77 | IGF1R (0.39) | — | |
| SCHEMBL4884428 | 0.77 | IGF1R (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | claimed |
| US-20070259891-A1 | Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1621539-A1 | Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | Aventis Pharma S.A. (FR) | 2006-02-01 | — | — | EP | disclosed |